KalVista Pharmaceuticals Unveils New Findings on Patient Satisfaction with EKTERLY® (sebetralstat) and Its Promise for Children Aged 2-11 at the ACAAI 2025 Annual Scientific Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Should l Buy KALV?
Source: Newsfilter
Patient Satisfaction with Sebetralstat: Participants in the KONFIDENT-S study who switched to sebetralstat reported high satisfaction levels, with 84% rating their experience as satisfied or better, highlighting the need for convenient, non-injectable treatment options for hereditary angioedema (HAE).
Pediatric Study Results: Interim results from the KONFIDENT-KID study indicate that sebetralstat is effective and well-tolerated in children aged 2-11, with a median time to symptom relief of 1.5 hours and no serious adverse events reported.
Expert Consensus on Treatment Barriers: A Delphi Consensus Study identified significant barriers to timely on-demand treatment for HAE, emphasizing the need for safe and effective oral therapies to improve patient adherence and reduce treatment delays.
Transformative Potential of EKTERLY: KalVista Pharmaceuticals aims to position EKTERLY (sebetralstat) as a foundational therapy for HAE management, particularly for pediatric patients, by providing a non-invasive oral treatment option that addresses the unmet needs of families affected by this condition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KALV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KALV
Wall Street analysts forecast KALV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.120
Low
29.00
Averages
34.38
High
39.00
Current: 15.120
Low
29.00
Averages
34.38
High
39.00
About KALV
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Needham Raises Kalvista Price Target to $35
- Price Target Increase: Needham raised the price target for Kalvista Pharmaceuticals Inc from $32 to $35, with analyst Serge Belanger maintaining a Buy rating, reflecting confidence in the company's future growth prospects.
- Market Performance: Kalvista shares closed at $15.82 on Thursday, indicating that despite the target price increase, the current stock price remains significantly below the new target, suggesting a potential undervaluation by the market.
- Competitive Analysis: In the biopharmaceutical sector, Kalvista's advancements in innovative drug development may attract increased investor interest, especially in light of the target price increase, which could stimulate stock price appreciation.
- Investor Confidence: The positive rating and target price increase from analysts may bolster investor confidence in Kalvista, potentially facilitating its future financing and market expansion plans.
See More
KalVista Launches EKTERLY, Achieves $35M in First-Year Revenue
- Positive Market Response: KalVista Pharmaceuticals reported approximately $35 million in net product revenue for its hereditary angioedema treatment EKTERLY in Q4 2025, indicating strong market demand through growing prescriber adoption and repeat prescriptions.
- Breakthrough Treatment: EKTERLY is the first and only oral on-demand treatment approved by the FDA in July 2025 for acute attacks in patients aged 12 and older, representing a significant advancement in the treatment landscape.
- Global Expansion Plans: KalVista granted Multicare Pharmaceuticals exclusive rights to commercialize sebetralstat in Latin America, covering Brazil, Argentina, Colombia, and Mexico, thereby enhancing its global market reach.
- Rapid Clinical Progress: The company completed enrollment in the Phase 3 KONFIDENT-KID trial evaluating sebetralstat in children aged 2 to 11 a full year ahead of schedule, with plans to submit a new drug application in Q3 2026 and a potential U.S. launch in 2027.
See More
Greenbrier Companies Inc Beats Q1 Earnings Estimates with $1.14 EPS and $706.1M Sales
- Earnings Beat: Greenbrier Companies Inc reported a Q1 earnings per share of $1.14, surpassing market expectations of $0.87, indicating strong performance that may boost investor confidence.
- Sales Surge: The company's quarterly sales reached $706.1 million, significantly exceeding the anticipated $626.297 million, demonstrating robust product demand that could enhance market share and competitiveness.
- Stock Fluctuation: Despite the positive earnings report, Greenbrier's stock fell 0.8% to $52.90 in after-hours trading, reflecting market concerns about the broader economic environment.
- Industry Impact: Greenbrier's strong financial results may positively influence the transportation and logistics sector, attracting more investor attention to related stocks and potentially driving overall industry recovery.
See More
General Motors Faces $7.1 Billion Loss from EV Investments, Stock Drops
- EV Investment Loss: General Motors is facing a staggering $7.1 billion loss from its electric vehicle investments, which has led to a 0.63% drop in its premarket stock price, reflecting market concerns over its future profitability.
- Market Reaction: Despite the significant loss, GM maintains a strong price trend in the short term, indicating investor confidence in its long-term strategy, although short-term stock volatility may increase.
- Industry Impact: This loss not only affects GM's financial health but could also negatively impact investor confidence across the entire electric vehicle sector, especially in an increasingly competitive market environment.
- Strategic Reevaluation Needed: GM must reassess its electric vehicle strategy to adapt to market changes and investor expectations, ensuring it remains competitive in the future electric vehicle market.
See More
Tilray Brands Reports Q2 Earnings Beat, Shares Surge 7.3%
- Earnings Beat: Tilray Brands reported Q2 earnings of $0.01 per share, surpassing the market expectation of a $0.20 loss, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved quarterly revenue of $217.51 million, exceeding the consensus estimate of $210.95 million, demonstrating success in market demand and sales strategies, which further solidifies its market position.
- Stock Price Surge: Following the positive earnings report, Tilray Brands' shares rose 7.3% to $9.80 in pre-market trading, reflecting investor optimism about the company's future growth potential.
- Positive Market Reaction: The strong performance post-earnings release may attract more investor attention, enhancing the company's appeal in a competitive market landscape.
See More
China SXT Pharmaceuticals Launches AI Initiative, Stock Rises 13.6%
- AI Initiative Launch: China SXT Pharmaceuticals announced the launch of its Strategic AI Insights Initiative, resulting in a 13.6% stock increase to $1.42, adding $0.17, aimed at integrating AI-driven analytics into product portfolio planning, thereby enhancing the company's innovation capabilities in modern traditional Chinese medicine.
- Acquisition Speculation Boost: Revolution Medicines' stock surged 15.1% to $123.65 following reports that Merck is in talks to acquire the company, while the FDA granted Breakthrough Therapy Designation to its zoldonrasib, further boosting market confidence.
- Optimistic Revenue Forecast: KalVista Pharmaceuticals reported preliminary unaudited global net product revenue results for Q4 and full year 2025, leading to a 14.0% stock increase to $18.04, reflecting investor optimism about the company's future performance.
- Clinical Progress Presentation: Sagimet Biosciences announced plans to present clinical trial results for its FASN inhibitor denifanstat at the upcoming MASH-TAG Conference, resulting in a 7.7% stock increase to $6.00, indicating market interest in its anti-fibrotic therapy potential.
See More
Needham Raises Kalvista Price Target to $35
- Price Target Increase: Needham raised the price target for Kalvista Pharmaceuticals Inc from $32 to $35, with analyst Serge Belanger maintaining a Buy rating, reflecting confidence in the company's future growth prospects.
- Market Performance: Kalvista shares closed at $15.82 on Thursday, indicating that despite the target price increase, the current stock price remains significantly below the new target, suggesting a potential undervaluation by the market.
- Competitive Analysis: In the biopharmaceutical sector, Kalvista's advancements in innovative drug development may attract increased investor interest, especially in light of the target price increase, which could stimulate stock price appreciation.
- Investor Confidence: The positive rating and target price increase from analysts may bolster investor confidence in Kalvista, potentially facilitating its future financing and market expansion plans.
See More
KalVista Launches EKTERLY, Achieves $35M in First-Year Revenue
- Positive Market Response: KalVista Pharmaceuticals reported approximately $35 million in net product revenue for its hereditary angioedema treatment EKTERLY in Q4 2025, indicating strong market demand through growing prescriber adoption and repeat prescriptions.
- Breakthrough Treatment: EKTERLY is the first and only oral on-demand treatment approved by the FDA in July 2025 for acute attacks in patients aged 12 and older, representing a significant advancement in the treatment landscape.
- Global Expansion Plans: KalVista granted Multicare Pharmaceuticals exclusive rights to commercialize sebetralstat in Latin America, covering Brazil, Argentina, Colombia, and Mexico, thereby enhancing its global market reach.
- Rapid Clinical Progress: The company completed enrollment in the Phase 3 KONFIDENT-KID trial evaluating sebetralstat in children aged 2 to 11 a full year ahead of schedule, with plans to submit a new drug application in Q3 2026 and a potential U.S. launch in 2027.
See More
Greenbrier Companies Inc Beats Q1 Earnings Estimates with $1.14 EPS and $706.1M Sales
- Earnings Beat: Greenbrier Companies Inc reported a Q1 earnings per share of $1.14, surpassing market expectations of $0.87, indicating strong performance that may boost investor confidence.
- Sales Surge: The company's quarterly sales reached $706.1 million, significantly exceeding the anticipated $626.297 million, demonstrating robust product demand that could enhance market share and competitiveness.
- Stock Fluctuation: Despite the positive earnings report, Greenbrier's stock fell 0.8% to $52.90 in after-hours trading, reflecting market concerns about the broader economic environment.
- Industry Impact: Greenbrier's strong financial results may positively influence the transportation and logistics sector, attracting more investor attention to related stocks and potentially driving overall industry recovery.
See More
General Motors Faces $7.1 Billion Loss from EV Investments, Stock Drops
- EV Investment Loss: General Motors is facing a staggering $7.1 billion loss from its electric vehicle investments, which has led to a 0.63% drop in its premarket stock price, reflecting market concerns over its future profitability.
- Market Reaction: Despite the significant loss, GM maintains a strong price trend in the short term, indicating investor confidence in its long-term strategy, although short-term stock volatility may increase.
- Industry Impact: This loss not only affects GM's financial health but could also negatively impact investor confidence across the entire electric vehicle sector, especially in an increasingly competitive market environment.
- Strategic Reevaluation Needed: GM must reassess its electric vehicle strategy to adapt to market changes and investor expectations, ensuring it remains competitive in the future electric vehicle market.
See More
Tilray Brands Reports Q2 Earnings Beat, Shares Surge 7.3%
- Earnings Beat: Tilray Brands reported Q2 earnings of $0.01 per share, surpassing the market expectation of a $0.20 loss, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved quarterly revenue of $217.51 million, exceeding the consensus estimate of $210.95 million, demonstrating success in market demand and sales strategies, which further solidifies its market position.
- Stock Price Surge: Following the positive earnings report, Tilray Brands' shares rose 7.3% to $9.80 in pre-market trading, reflecting investor optimism about the company's future growth potential.
- Positive Market Reaction: The strong performance post-earnings release may attract more investor attention, enhancing the company's appeal in a competitive market landscape.
See More
China SXT Pharmaceuticals Launches AI Initiative, Stock Rises 13.6%
- AI Initiative Launch: China SXT Pharmaceuticals announced the launch of its Strategic AI Insights Initiative, resulting in a 13.6% stock increase to $1.42, adding $0.17, aimed at integrating AI-driven analytics into product portfolio planning, thereby enhancing the company's innovation capabilities in modern traditional Chinese medicine.
- Acquisition Speculation Boost: Revolution Medicines' stock surged 15.1% to $123.65 following reports that Merck is in talks to acquire the company, while the FDA granted Breakthrough Therapy Designation to its zoldonrasib, further boosting market confidence.
- Optimistic Revenue Forecast: KalVista Pharmaceuticals reported preliminary unaudited global net product revenue results for Q4 and full year 2025, leading to a 14.0% stock increase to $18.04, reflecting investor optimism about the company's future performance.
- Clinical Progress Presentation: Sagimet Biosciences announced plans to present clinical trial results for its FASN inhibitor denifanstat at the upcoming MASH-TAG Conference, resulting in a 7.7% stock increase to $6.00, indicating market interest in its anti-fibrotic therapy potential.
See More
